Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri, Dana-Farber Cancer Institute.Two posters will be presented on the preclinical evaluation and human pharmacokinetics/ pharmacodynamics of casdatifan, respectively, and a third poster will be presented on AB801, Arcus’s AXL inhibitor.Arcus will also host a conference call to discuss the ARC-20 results at 5:00 AM PT / 8:00 AM ET on Thursday, October 24, 2024. HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being presented include a growing body of
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire
- Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics | DelveInsight [Yahoo! Finance]Yahoo! Finance
RCUS
Earnings
- 11/6/24 - Beat
RCUS
Sec Filings
- 12/20/24 - Form 4
- 12/17/24 - Form SC
- 12/17/24 - Form 4
- RCUS's page on the SEC website